| Literature DB >> 28567186 |
Min Hoe Chew1, Yu-Ting Yeh1, Ee-Lin Toh1, Stephen Aditya Sumarli1, Ghee Kheng Chew1, Lui Shiong Lee1, Mann Hong Tan1, Tiffany Priyanthi Hennedige1, Shin Yi Ng1, Say Kiat Lee1, Tze Tec Chong1, Hairil Rizal Abdullah1, Terence Lin Hon Goh1, Mohamed Zulfikar Rasheed1, Kok Chai Tan1, Choong Leong Tang1.
Abstract
AIM: To critically appraise short-term outcomes in patients treated in a new Pelvic Exenteration (PE) Unit.Entities:
Keywords: Advanced pelvic tumour; Chordoma; Colorectal cancer; Oncological outcome; Pelvic exenteration; Sacrectomy
Year: 2017 PMID: 28567186 PMCID: PMC5434389 DOI: 10.4251/wjgo.v9.i5.218
Source DB: PubMed Journal: World J Gastrointest Oncol
Figure 1Total pelvic and lateral exenteration. A: A Deaver retractor was placed caudally (White arrow: Pelvic tumour; Yellow arrow: Right obturator nerve; Blue and purple arrows: Right internal iliac vein and artery respectively; Green arrow: Transected right distal ureter at pelvic brim with infant feeding tube inserted for intraoperative urinary diversion); B: Post-exenteration view showing the right internal iliac vessels, obturator nerve and pelvic lymph nodes excised and the metal vacuum tube pointed at exposed pelvic bone (Yellow arrow: Sciatic nerve; Blue arrow: Right external iliac vessels; Green arrow: Transected right distal ureter); C: Cicatrising tumour specimen showing invasion into bladder and right pelvic sidewall (Blue arrow: Right internal iliac vessels).
Figure 2Demonstration of abdominal perineal approach for level S3 sacrectomy. The left panel (perineal view) demonstrates placement of the osteotomes posterior to the sacral bone in order to protect perineal skin while the surgeon transects the sacrum at S3 level in the right panel (abdominal view).
Characteristics of patients who underwent pelvic exenteration
| Sex, | |
| Male | 16 (64) |
| Female | 9 (36) |
| Age, | Median, 61.9 yr (range, 30-72) |
| ASA score, | I: 11 (44) |
| II: 13 (52) | |
| III: 1 (4) | |
| Median, 2 | |
| ECOG status | 0: 22 (88) |
| 1: 2 (8) | |
| 3: 1 (4) | |
| Median, 0 | |
| Co-morbidities, | |
| Hypertension | 6 (24) |
| Diabetes mellitus | 5 (20) |
| Hyperlipidaemia | 8 (32) |
| Ischaemic heart disease | 1 (4) |
| Primary cancer type ( | |
| Colorectal | 12 |
| Chordoma | 3 |
| Gynaecological | 1 |
| Recurrent cancer type ( | |
| Colorectal | 6 |
| Gynaecological | 3 |
ASA: American Society of Anesthesiologists; ECOG: Eastern Cooperative Oncology Group.
Pre-operative and operative treatment details
| Incidence of neoadjuvant chemoradiation | |
| Primary cancer | |
| Colorectal | 75% |
| Chordoma | 0% |
| Gynaecological | 0% |
| Recurrent cancer | |
| Colorectal | 67% |
| Gynaecological | 0% |
| Operative procedure, | |
| Total PE | 1 (4) |
| Total PE with lateral exenteration | 9 (36) |
| Anterior PE | 3 (12) |
| Anterior and Lateral PE | 1 (4) |
| Posterior PE | 2 (8) |
| Posterior and Lateral PE | 5 (20) |
| Lateral PE | 4 (16) |
| Sacrectomy combined with any above PE procedures | 9 (36) |
PE: Pelvic exenteration.
Clavien-Dindo classification of surgical complications, n = 12
| 2 | Wound infection | 6 |
| Urinary tract infection | 4 | |
| Venous access infection | 4 | |
| Prolonged ileus | 1 | |
| Deep vein thrombosis | 1 | |
| Acute myocardial infarction | 1 | |
| 3 | Postoperative bleeding: Re-laparotomy | 1 |
| Donor site-infected seroma percutaneous drainage | 1 | |
| 4 | Temporary renal dialysis | 1 |
| Total adverse events | 20 |
Characteristics of post-pelvic exenteration recurrent diseases
| Primary | Colonic | 0 | 0 | 1 | 1 | 0 |
| Primary | Rectal | 0 | 1 | 1 | 0 | 2 |
| Primary | Sacral chordoma | 1 | 0 | 0 | 1 | 0 |
| Recurrent | Rectal | 1 | 0 | 0 | 0 | 1 |
| Recurrent | Cervical | 0 | 1 | 1 | 2 | 0 |
| Total | 2 | 2 | 3 | 4 | 3 |
Both microscopic resection margin status and pre-exenteration primary or recurrent tumours do not show any statistically significant influence on post-exenteration recurrence (P = 0.67). PE: Pelvic Exenteration.